Literature DB >> 32487652

Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy.

Takanori Abe1, Nao Kobayashi2, Tomomi Aoshika2, Yasuhiro Ryuno2, Satoshi Saito2, Mitsunobu Igari2, Ryuta Hirai2, Y U Kumazaki2, Y U Miura3, Kyoichi Kaira3, Hiroshi Kagamu3, Shin-Ei Noda2, Shingo Kato2.   

Abstract

BACKGROUND/AIM: The treatment outcome of locally advanced non-small cell lung cancer (LA-NSCLC) has been improved over the past years but local failure is still common for these patients. The purpose of this study is to analyze the pattern of local failure and its risk factor of concurrent chemo-radiotherapy (CCRT) for locally advanced LA-NSCLC. PATIENTS AND METHODS: We evaluated 77 patients treated with CCRT for LA-NSCLC from July 2007 to December 2017 at our institution. Most of the patients were treated with 60 Gy in 30 fractions of radiotherapy and concurrent chemotherapy. The median follow-up time was 26 months.
RESULTS: Among the 77 patients, 50 developed progressive disease during follow-up, including 14 with only local recurrence (LR), 10 with only distant metastasis and 26 with both. Of the 14 patients with only LR, 12 had primary tumor recurrence and 2 had recurrence in lymph nodes. A primary tumor volume of 50 cm3 was identified as the optimal cut-off value that was significantly correlated with primary tumor recurrence and overall survival.
CONCLUSION: Primary tumor recurrence without lymph node and distant metastasis was observed in 12 patients (16%). Primary tumor volume of 50 cm3 was the optimal cut-off value for the prediction of primary tumor recurrence. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Local failure; concurrent chemo-radiotherapy; locally advanced non-small cell lung cancer

Year:  2020        PMID: 32487652     DOI: 10.21873/anticanres.14339

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer.

Authors:  Carsten Nieder; Kristian S Imingen
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

2.  Sleep Disturbances in Lung Cancer Patients Assigned to Definitive or Adjuvant Irradiation.

Authors:  Dirk Rades; Svenja Kopelke; Soeren Tvilsted; Troels W Kjaer; Steven E Schild; Tobias Bartscht
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

3.  Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.

Authors:  Takanori Abe; Satoshi Saito; Misaki Iino; Tomomi Aoshika; Yasuhiro Ryuno; Tomohiro Ohta; Mitsunobu Igari; Ryuta Hirai; Yu Kumazaki; Yu Miura; Kyoichi Kaira; Hiroshi Kagamu; Shin-Ei Noda; Shingo Kato
Journal:  Thorac Cancer       Date:  2020-12-01       Impact factor: 3.223

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.